# Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

> **NCT00436917** · NA · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 60 (actual)

## Conditions studied

- Breast Cancer
- Osteoporosis

## Interventions

- **DRUG:** zoledronic acid
- **PROCEDURE:** Letrozole as adjuvant therapy

## Key facts

- **NCT ID:** NCT00436917
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2008-06
- **Final completion:** 2016-05-09
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436917, "Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00436917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*